Bayer’s Response to “Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis”

JAMA ◽  
2004 ◽  
Vol 292 (21) ◽  
pp. 2655 ◽  
Author(s):  
Joseph D. Piorkowski
JAMA ◽  
2004 ◽  
Vol 292 (21) ◽  
pp. 2622 ◽  
Author(s):  
Bruce M. Psaty ◽  
Curt D. Furberg ◽  
Wayne A. Ray ◽  
Noel S. Weiss

Sign in / Sign up

Export Citation Format

Share Document